Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PITRESSIN TANNATE is a vasopressin tannate injectable indicated for antidiuretic replacement therapy and variceal bleeding control. It is a synthetic analog of the natural antidiuretic hormone (ADH) that works by stimulating vasopressin receptors to increase water reabsorption and induce vasoconstriction. The product is currently in pre-launch development by Pfizer.
Pre-Launch
Pre-launch stage indicates early commercial buildout with priority on launch readiness, market access, and field team recruitment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PITRESSIN TANNATE offers the high-visibility opportunity of a product launch at a major pharmaceutical company, with roles spanning commercial strategy, field sales, and medical affairs. Pre-launch positions carry elevated responsibility for market education, payer engagement, and field force scaling ahead of approval.
Brand ManagerField Sales Representative
Worked on PITRESSIN TANNATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.